Cosmo Pharmaceuticals N.V. invites investors, financial analysts as well as business and trade media to a conference call Q&A session on the 4th of May 2021 to discuss GI Genius™, the first device approved by the US Food and Drug Administration[1] that uses artificial intelligence to help detect potential signs of colon cancer.
DUBLIN, April 28, 2021 /PRNewswire/ -- Cosmo Pharmaceuticals N.V. (SIX: COPN) ( XETRA: C43) invites investors, financial analysts as well as business and trade media to a conference call Q&A session on the 4th of May 2021 to discuss GI Genius™, the first device approved by the US Food and Drug Administration[1] (FDA) that uses artificial intelligence to help detect potential signs of colon cancer. GI Genius™ is also approved in Europe, Australia, Israel and the United Arab Emirates and is available under an exclusive worldwide distribution agreement with Medtronic.
The following representatives from Cosmo will be available to explain how GI Genius™ helps to address the challenges of preventing colorectal cancer and empowers physicians to detect colorectal polyps (please note that financial details will be discussed at a later date):
Mauro Ajani, Chairman
Alessandro Della Chà, CEO
Andrea Cherubini, Head of Artificial Intelligence
Nhan Ngo Dinh, Head of Research and Development, AI and Biomedical IT
Niall Donnelly, CFO & Head of Investor Relations
Date: Tuesday, May 4, 2021
Time: 04:00 pm CET
Dial-in numbers:
Switzerland / Europe, +41 (0) 58 310 50 00
United Kingdom, +44 (0) 207 107 0613
United States, +1 (1) 631 570 5613
About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius™ its artificial intelligence device that uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo® to Red Hill Biopharma Ltd. for the US and has licensed Relafalk® to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company’s website: www.cosmopharma.com
Calendar
Annual General Meeting, Amsterdam, May 28, 2021
Half-Year 2021 Report, July 30, 2021
Contact
Niall Donnelly, CFO & Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
ndonnelly@cosmopharma.com
Logo - https://mma.prnewswire.com/media/1459450/Cosmo_Pharmaceuticals_Logo.jpg
[1] GI Genius™ was approved by the FDA on the 9th of April 2021: https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-device-uses-artificial-intelligence-help-detect-potential-signs-colon
View original content:http://www.prnewswire.com/news-releases/invitation-to-cosmos-gi-genius-qa-session-for-investors-analysts-and-journalist-301278852.html
SOURCE Cosmo Pharmaceuticals N.V.
Company Codes: Swiss:COPN, OTC-PINK:CMOPF, Munich:C43, LSE:0RGI, Frankfurt:C43
